BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of MPS IIIB (Sanfilippo B Syndrome)
Go back to BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of MPS IIIB (Sanfilippo B Syndrome)| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 64.92 -0.16 (0.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.08 | 52 Week High | $108.96 | |||
| Open | $65.25 | 52 Week Low | $62.12 | |||
| Day High | $65.29 | P/E | N/A | |||
| Day Low | $64.75 | EPS | $-1.27 | |||
| Volume | 452,256 | |||||
